VXCO-100
- Generic Name
- VXCO-100
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Phase 1
Completed
- Conditions
- SARS-CoV-2SARS-CoV
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Vaccine Company, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT05938075
- Locations
- 🇿🇦
Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Academic Hospital, Johannesburg, Gauteng, South Africa
🇿🇦HIV and other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council, Botha's Hill, Kwa-Zulu Natal, South Africa
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Vaccine Company, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT05870839
- Locations
- 🇺🇸
University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States
🇺🇸The Hope Clinic of Emory University, Decatur, Georgia, United States
🇺🇸University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath